Dual function of ERRα in breast cancer and bone metastasis formation: Implication of VEGF and osteoprotegerin

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5728-5738

  Fradet, Anaïs ^a,b   Sorel, Helène ^a,b   Bouazza, Lamia ^a,b   Goehrig, Delphine ^a,b   Dépalle, Baptiste ^a,b   Bellahcène, Akeila ^d   Castronovo, Vincent ^d   Follet, Hélène ^a,b   Descotes, Françoise ^c   Aubin, Jane E ^e   Clézardin, Philippe ^a,b   Bonnelye, Edith ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RELATED RECEPTOR ALPHA; MESSENGER RNA; OSTEOPROTEGERIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OSTEOCLAST; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPROTEGERIN; RECEPTORS, ESTROGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052213519     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1431     Document Type: Article

References (46)

1. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
2. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005;10:169-80. (Pubitemid 41031006)
3. Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 2007;24:599-608.
4. Clezardin P. Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class. Bone Epub2010 Jul 22.
5. Benoit G, Cooney A, Giguere V, Ingraham H, Lazar M, Muscat G, et al. International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev 2006;58:798-836. (Pubitemid 44833747)
6. Kallen J, Schlaeppi JM, Bitsch F, Filipuzzi I, Schilb A, Riou V, et al. Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERRalpha): crystal structure of ERRalpha ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1alpha. J Biol Chem 2004;279:49330-7. (Pubitemid 39625820)
7. Greschik H, Wurtz JM, Sanglier S, Bourguet W, van Dorsselaer A, Moras D, et al. Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol Cell 2002;9:303-13. (Pubitemid 34195556)
8. Giguere V, Yang N, Segui P, Evans RM. Identification of a new class of steroid hormone receptors. Nature 1988;331:91-4. (Pubitemid 18053426)
9. Busch BB SWJ, Martin R, Ordentlich P, Zhou S, Sapp DW, Horlick RA, et al. Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha. J Med Chem 2004;47:5593-6.
10. Willy PJ, Murray IR, Qian J, Busch BB, Stevens WC, Martin R, et al. Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc Natl Acad Sci U S A 2004;101:8912-7. (Pubitemid 38781585)
11. Lui K TT, Mori T, Zhou D, Chen S. MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands. Biochem Pharmacol 2008;76:208-15.
12. Luo J, Sladek R, Carrier J, Bader JA, Richard D, Giguere V. Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor alpha. Mol Cell Biol 2003;23:7947-56. (Pubitemid 37377488)
13. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A, et al. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab 2007;6:5-37.
14. Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 2002;62:6510-8. (Pubitemid 35364116)
15. Suzuki T, Miki Y, Moriya T, Shimada N, Ishida T, Hirakawa H, et al. Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Res 2004;64:4670-6. (Pubitemid 38856942)
16. Cheung CP, Yu S, Wong KB, Chan LW, Lai FM, Wang X, et al. Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab 2005;90:1830-44. (Pubitemid 40464058)
17. Gao M, Sun P, Wang J, Zhao D, Wei L. Expression of estrogen receptor-related receptor isoforms and clinical significance in endometrial adenocarcinoma. Int J Gynecol Cancer 2006;16:827-33.
18. Cavallini A, Notarnicola M, Giannini R, Montemurro S, Lorusso D, Visconti A, et al. Oestrogen receptor-related receptor alpha (ERRalpha) and oestrogen receptors (ERalpha and ERbeta) exhibit different gene expression in human colorectal tumour progression. Eur J Cancer 2005;41:1487-94. (Pubitemid 40826474)
19. Sun P, Sehouli J, Denkert C, Mustea A, Könsgen D, Koch I, et al. Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J Mol Med 2005;83:457-67. (Pubitemid 40922168)
20. Stein RA, McDonnell DP. Estrogen-related receptor {alpha} as a therapeutic target in cancer. Endocr Relat Cancer 2006;13 Suppl 1:S25-32. (Pubitemid 46219246)
21. Bonnelye E, Merdad L, Kung V, Aubin JE. The orphan nuclear estrogen receptor-related receptor (ERR) is expressed throughout osteoblast differentiation and regulates bone formation in vitro. J Cell Biol 2001;153:971-83. (Pubitemid 34289237)
22. Bonnelye E, Zirngibl RA, Jurdic P, Aubin JE. The orphan nuclear estrogen receptor-related receptor-{alpha} regulates cartilage formation in vitro: implication of Sox9. Endocrinology 2007;148:1195-205.
23. Bonnelye E, Saltel F, Chabadel A, Zirngibl RA, Aubin JE, Jurdic P. Involvement of the orphan nuclear estrogen receptor-related receptor ERRalpha in osteoclast adhesion and transmigration. J Mol Endocrinol 2010;45:365-77.
24. Rajalin AM PH, Aarnisalo P. ERRalpha regulates osteoblastic and adipogenic differentiation of mouse bone marrow mesenchymal stem cells. Biochem Biophys Res Commun 2010;396:477-82.
25. Delhon I, Gutzwiller S, Morvan F, Rangwala S, Wyder L, Evans G, et al. Absence of estrogen receptor related alpha increases osteoblastic differentiation and cancellous bone mineral density. Endocrinology 2009;150:4463-72.
26. Teyssier CGM, Rabier B, Monfoulet L, Dine J, Macari C, Espallergues J, et al. Absence of ERRalpha in female mice confers resistance to bone loss induced by age or estrogen-deficiency. PLoS One 2009;4:e7942.
27. Wei W WX, Yang M, Smith LC, Dechow PC, Sonoda J, Evans RM, et al. PGC1beta mediates PPARgamma activation of osteoclastogenesis androsiglitazone-induced bone loss. Cell Metab 2010;11:503-16.
28. Bonnelye E, Vanacker JM, Dittmar T, Begue A, Desbiens X, Denhardt DT, et al. The ERR-1 orphan receptor is a transcriptional activator expressed during bone development. Mol Endocrinol 1997;11:905-16. (Pubitemid 27241783)
29. Vanacker JM, Delmarre C, Guo X, Laudet V. Activation of the osteopontin promoter by the orphan nuclear receptor estrogen receptor related alpha. Cell Growth Differ 1998;9:1007-14. (Pubitemid 29036195)
30. Zirngibl RA CJ, Aubin JE. Estrogen receptor-related receptor alpha (ERRalpha) regulates osteopontin expression through a non-canonical ERRalpha response element in a cell context-dependent manner. J Mol Endocrinol 2008;40:61-73. (Pubitemid 351279510)
31. Berthier ASS, Sasco AJ, Bobin JY, De Laroche G, Datchary J, Saez S, et al. High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer. Br J Cancer 2010;102:1024-31.
32. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-34. (Pubitemid 32995393)
33. Le Gall CBA, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007;67:9894-902. (Pubitemid 47621238)
34. David MWE, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, et al. Cancer cell expression of autotaxin controls bone metastasisformation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 2010;5:e9741.
35. Boissier SFM, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54. (Pubitemid 30395820)
36. Vanacker JM, Pettersson K, Gustafsson JA, Laudet V. Transcriptional targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. Embo J 1999;18:4270-9. (Pubitemid 29364129)
37. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42. (Pubitemid 40852708)
38. Rachner TDBP, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 2009;108:106-16.
39. Malyankar UMSM, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000;275:20959-62. (Pubitemid 30481782)
40. McGonigle JSGC, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009;12:35-46.
41. Fisher JLT-MR, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 2006;66:3620-8.
42. Stein R, Gaillard S, McDonnell D. Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. J Steroid Biochem Mol Biol 2009;114:106-12.
43. Benslimane-Ahmim Z, Heymann D, Dizier B, Lokajczyk A, Brion R, Laurendeau I, et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost 2011;9:834-43.
44. Dwyer MAJJ, Wade HE, Eaton ML, Kunder RS, Kazmin D, Chang CY, et al. WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res 2010;22:9298-308.
45. Lu XYC, Yuan M, Wei Y, Hu G, Kang Y. In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res 2010;70:3905-14.
46. Fei JPF, Malaval L, Vico L, Lafage-Proust MH. Imaging and quantitative assessment of long bone vascularization in the adult rat using microcomputed tomography. Anat Rec (Hoboken) 2010;293:215-24.